AchillesLatest News

ACHILLES THERAPEUTICS RECEIVES CTA APPROVAL FOR PHASE I/II STUDY IN METASTIC OR RECURRENT MELANOMA – Second CTA approval in 2019 – the first was for a NSCLC study

13/02/2019

Stevenage, UK 13 February 2019 – Achilles Therapeutics (“Achilles”), a biopharmaceutical company developing personalised cancer immunotherapies, today announces the approval by...

Read More +

ACHILLES THERAPEUTICS APPOINTS DR MARKUS DANGL AS CHIEF SCIENTIFIC OFFICER

12/02/2019

Stevenage, UK 12 February 2019 – Achilles Therapeutics (“Achilles”), a biopharmaceutical company developing personalised cancer immunotherapies, today announces the appointment of...

Read More +

ACHILLES THERAPEUTICS RECEIVES CTA APPROVAL FOR PHASE I/II STUDY IN NON-SMALL CELL LUNG CANCER – Ground-breaking clinical trial in patients with significant unmet medical need to start this year

21/01/2019

Stevenage, UK 21 January 2019 – Achilles Therapeutics (“Achilles”), a biopharmaceutical company developing personalised cancer immunotherapies, today announces that its Clinical...

Read More +

ACHILLES THERAPEUTICS APPOINTS DR EDWIN MOSES AS CHAIRMAN OF ITS BOARD OF DIRECTORS AND DR IRAJ ALI AS CHIEF EXECUTIVE OFFICER

10/12/2018

Stevenage, UK; 10 December 2018 – Achilles Therapeutics (“Achilles” or “the Company”), a biopharmaceutical company using neoantigens to develop personalised cancer...

Read More +

ACHILLES TODAY ANNOUNCES THAT IT HAS APPOINTED SENIOR PHARMACEUTICAL EXECUTIVE MICHAEL F. GIORDANO, M.D., TO ITS BOARD OF DIRECTORS.

19/09/2018

Stevenage, 19 September 2018 – Achilles Therapeutics (“Achilles”), a biopharmaceutical company developing novel cancer immunotherapies targeting clonal neoantigens, today announced that it...

Read More +

ACHILLES’ FOUNDERS MAP TRUNCAL AND BRANCHED MUTATIONS AND COPY NUMBER EVENTS TO PREDICT EARLY RELAPSE IN NON-SMALL CELL LUNG CANCER.

26/04/2017

Achilles Founders map truncal and branched mutations and copy number events to predict early relapse in non-small cell cancer lungs, opening...

Read More +

ACHILLES STARTS 2017 WITH MOVE TO STEVENAGE BIOSCIENCE CATALYST

03/01/2017

Achilles Therapeutics starts 2017 with move to Stevenage Bioscience Catalyst Immunotherapy company joins growing cell & gene therapy community on campusStevenage, UK,...

Read More +

ACHILLES LAUNCHES WITH FUNDS OF £13.2M TO DEVELOP IMMUNOTHERAPIES FOR CANCER

28/09/2016

ACHILLES THERAPEUTICS LAUNCHED WITH FUNDS OF £13.2 MILLION TO DEVELOP IMMUNOTHERAPIES FOR CANCER Wednesday 5 October, 2016 SYNCONA LLP and CANCER...

Read More +